Effects of Hypertension and Exercise on Cardiac Proteome Remodelling
Table 1
Cardiac proteome modulated by pathologic cardiac hypertrophy.
Experimental model
Experimental method
Main altered proteome
Reference
SHR and WKY
2D-DIGE
Comparison between different SHR age and animal models: (i) 33 mitochondrial proteins with altered expression between SHR groups; (ii) Hadha and NDUFA10 with differential patterns in SHR versus WKY.
Protein phosphorylation in cardiac hypertrophy linked with hypertension: (i) 3-ketoacyl-CoA thiolase; (ii) α-enolase hyperphosphorilation (reduced enzymatic activity); (iii) SR-Ca2+-ATPase and phospholamban.
Comparison between two distinct models of heart hypertrophy: (i) 29 protein spots with differential expression among the three groups (18 proteins identified); (ii) GSTM2 and SCAD in RHR versus WKY; (iii) Distinct profile of GSTM2 and SCAD between SHR and RHR.
Effect of pharmacologic treatment over LVH regression: (i) 36 proteins altered in hypertensive heart; (ii) SCAD, NADH, enolase 1, and aldehyde dehydrogenase; (iii) ETF-, superoxide dismutase, and thiol-specific antioxidant.
Animal model lacking Kir6.2 ATP-sensitive K(+) (K(ATP)) channels
2-DE; LC-MS/MS; Orbitrap MS
Deficiency in myocardial KATP channels and hypertension pathophysiology: (i) 170 proteins with differential expression in response to KATP channel dysfunction; (ii) LDH, SCAD, pyruvate kinase, TPI, and CK.
Proteinases and the pathophysiology of hypertension: (i) Induction of cardiac hypertrophy by Ang II; (ii) Attenuation of cardiac hypertrophy by Ang II and RAS inhibition.
Caloric restriction in dTGR over mitochondrial proteins: (i) 7 differential proteins after caloric restriction in Dtgr; (ii) 6 proteins unique to dTGR compared to caloric restricted dTGR and SD rats; (iii) 6 proteins (cytoskeletal and enzyme modulators) and oxidoreductase.
Cardiac hypertrophy induced by ET-1 and leukemic inhibitory factor exposure: (i) Differential proteome between ET-1 (concentric) and eccentric induced hypertrophy; (ii) B-crystalline in nontreated cells; (iii) ANP upregulated in both cardiac hypertrophy models; (iv) desmin protein species.
Cardiac hypertrophy induced by ISO: (i) 7 differential expressions in heart induced with ISO; (ii) MLC 2 and 3, desmin, prohibitin, FABP-H, and ATP-synthase 5; (iii) HSP60, 70, and D1.